The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | Combining bortezomib and lenalidomide-based regimens for frontline MM
Frontline transplant-ineligible multiple myeloma (MM) is typically treated with VMP (bortezomib, melphalan, prednisolone) or Rd (lenalidomide, dexamethasone) based regimens. However, efforts have recently been made to combine these treatments, as discussed here by Kwee Yong, PhD, FRCP, FRCPath, from University College London, London, UK. Prof. Yong highlights the RVd (lenalidomide, bortezomib, dexamethasone) lite treatment protocol, as well as alternating or sequential regimens.
